The effect of age on emotion processing in individuals with mood disorders and in healthy individuals

Copyright \ua9 2024 Gray, Moot, Frampton, Douglas, Gallagher, Jordan, Carter, Inder, Crowe, McIntosh and Porter. Introduction: Emotion processing is an essential part of interpersonal relationships and social interactions. Changes in emotion processing have been found in both mood disorders and in aging, however, the interaction between such factors has yet to be examined in detail. This is of interest due to the contrary nature of the changes observed in existing research - a negativity bias in mood disorders versus a positivity effect with aging. It is also unclear how changes in non-emotional cognitive function with aging and in mood disorders, interact with these biases. Methods and results: In individuals with mood disorders and in healthy control participants, we examined emotional processing and its relationship to age in detail. Data sets from two studies examining facial expression recognition were pooled. In one study, 98 currently depressed individuals (either unipolar or bipolar) were compared with 61 healthy control participants, and in the other, 100 people with bipolar disorder (in various mood states) were tested on the same facial expression recognition task. Repeated measures analysis of variance was used to examine the effects of age and mood disorder diagnosis alongside interactions between individual emotion, age, and mood disorder diagnosis. A positivity effect was associated with increasing age which was evident irrespective of the presence of mood disorder or current mood episode. Discussion: Results suggest a positivity effect occurring at a relatively early age but with no evidence of a bias toward negative emotions in mood disorder or specifically, in depressed episodes. The positivity effect in emotional processing in aging appears to occur even within people with mood disorders. Further research is needed to understand how this fits with negative biases seen in previous studies in mood disorders

An integrated safety analysis of combined acetaminophen and ibuprofen (Maxigesic®/ Combogesic®) in adults

Phillip Aitken,1 Ioana Stanescu,1 Rebecca Playne,1 Jennifer Zhang,1 Christopher MA Frampton,2 Hartley C Atkinson1 1Drug Development, AFT Pharmaceuticals Ltd, Auckland, New Zealand; 2Department of Medicine, University of Otago, Christchurch, New Zealand Introduction: Acetaminophen (APAP) and ibuprofen (IBP) are two analgesic compounds with a long history of use. Both are considered safe at recommended over-the-counter daily doses. Chronic use, high doses, or concomitant medication can produce safety risks for both drugs. APAP is associated with increased risk of hepatic injury, while IBP can produce gastric bleeding and thromboembolic events. Using a combination of APAP and IBP provides superior analgesia without transgressing daily dose limits of each individual drug.Methods: The present study aimed to determine if treatment with a fixed-dose combination (FDC) containing APAP and IBP results in any unexpected adverse events (AEs) and/or changes in the safety profiles of its two ingredients compared to monotherapy. The analysis will examine clinical safety data obtained from either single dose trials, multiple dose trials, a long-term exposure trial, and post-marketing surveillance data of APAP/IBP FDC tablets (Maxigesic®/Combogesic®, AFT Pharmaceuticals Ltd). The largest dataset was obtained by pooling the four randomized-controlled, multiple-dose clinical studies with either APAP 325 mg + IBP 97.5 mg (FDC 325/97.5, three tablets per dose) or APAP 500 mg + IBP 150 mg (FDC 500/150, two tablets per dose). At maximum doses, the two FDCs are bioequivalent, permitting the pooling of data for the analysis of safety. Results: A safety population of 922 patients who received full doses of either FDC, APAP alone, IBP alone, or placebo was compiled from the four studies. A total of 521 AEs were experienced with the incidence of FDC AEs similar to or below either monotherapy group or placebo. The FDC did not alter the incidence and percentage of the most common AEs, including gastrointestinal events and postoperative bleeding. Conclusion: Overall, the FDC is well tolerated and has a strong safety profile at single and multiple doses with improved efficacy over monotherapy. Keywords: paracetamol, nonsteroidal anti-inflammatory drugs, surgical pain, postoperative analgesia, multimodal pain managemen

Measuring change in cannabis use

© 2014 Informa UK Ltd. We examined the ability of the Cannabis User Disorders Identification Test - Revised (CUDIT-R) to detect change in a treatment sample, including correlation with changes in other clinically relevant areas of functioning, and to determine reliable and clinically significant change thresholds. 133 cannabis-using patients taking part in a treatment trial for concurrent substance use and mood disorder were administered the 8-item CUDIT-R at baseline, 6 and 12 months, in addition to assessment of current cannabis use disorder, mood, alcohol use, motivation and employment status. Significant reductions in CUDIT-R scores were observed and were correlated with change in cannabis diagnosis, and improvement in mood. Higher motivation at baseline predicted greater reduction in CUDIT-R score. Reliable change was identified as occurring when CUDIT-R score changed by two or more, while clinically significant change, benchmarked against an increase or decrease of one DSM-IV cannabis dependence symptom, was equated to a CUDIT-R score changing by 3 or more points

Fibrinogen and hemoglobin predict near future cardiovascular events in asymptomatic individuals

10.1038/s41598-021-84046-7Scientific Reports1114605-complete